natgillin/translations-raw huggingface dataset:
Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.
Radiofarmacevtska zdravila se bodo shranjevala v skladu z nacionalnimi predpisi o radioaktivnih snoveh.
Erasmus phase I/II study was a monocentric single arm open-label study to evaluate the efficacy of Lutathera (7,400 MBq administered for 4 times every 8 weeks) co-administered with amino acid solution in patients with somatostatin receptor positive tumours.
faze je bila monocentrična, odprta študija z eno skupino za preverjanje učinkovitosti zdravila Lutathera (7.400 MBq aplicirano 4-krat vsakih 8 tednov) sočasno z raztopino aminokislin pri bolnikih s tumorji s pozitivnimi somatostatinskimi receptorji.
• The short needle should be then connected to the pre-filled infusion set.
• Kratko iglo je treba nato priključiti na napolnjeni komplet za infuzijo.
Haematocrit decreased Protein urine
Proteini v urinu Zmanjšanje telesne mase
Specification of commercially available amino acid solutions Characteristic
Preglednica 2: Specifikacije komercialno dostopnih raztopin aminokislin Lastnosti
Administration of Lutathera and conduct of the procedure Lutathera is administered directly into a vein.
Apliciranje zdravila Lutathera in izvedba postopka Zdravilo Lutathera vam injicirajo neposredno v veno.
The absence of inhibition or significant induction of the human CYP450 enzymes, the absence of specific interaction with P-glycoprotein (efflux transporter) as well as OAT1, OAT3, OCT2, OATP1B1, OATP1B3, OCT1 and BCRP transporters in pre-clinical studies suggest that Lutathera has a low probability of causing significant other drug-drug interactions.
Odsotnost inhibicije ali znatne indukcije humanih encimov CYP450, odsotnost specifične interakcije s P-glikoproteinom (efluksnim transporterjem) in s transporterji OAT1, OAT3, OCT2, OATP1B1,
Individual benefit/risk justification
Presoja tveganja in koristi pri posameznem bolniku
No statistically significant difference in PFS was observed between the subgroup of patients who did not receive octreotide LAR (25.4 months [95% CI 22.8-30.6]) versus the subgroup who did receive concomitant treatment with octreotide LAR (30.9 months [95% CI 25.6-34.8]) (p= 0.747).
Pri PFS ni bilo statistično pomembnih razlik med podskupino bolnikov, ki ni prejemala oktreotida LAR (25,4 meseca [95-% IZ, 22,8-30,6]),
The hazard ratio for Lutathera was 0.18 (95% CI: 0.11 - 0.29), indicating 82% reduction in the risk for a patient to progress or die under Lutathera compared to octreotide LAR.
Razmerje tveganja za zdravilo Lutathera je bilo 0,18 (95-% IZ: 0,11-0,29), kar kaže na 82-% zmanjšanje tveganja za bolnika za napredovanje bolezni ali smrt pri zdravilu Lutathera v primerjavi z oktreotidom LAR.
As this medicinal product is known to be substantially excreted by the kidneys, patients with mild to moderate impaired renal function should be more frequently monitored during the treatment.
Znano je, da so to zdravilo v glavnem izloča preko ledvic, zato je treba bolnike z blago do zmerno ledvično okvaro med zdravljenjem pogosteje spremljati.
Lysine content
Vsebnost lizina
If necessary, patients may be treated with short acting somatostatin analogues during the 4 weeks preceding Lutathera administration, until 24 hours before the administration of Lutathera.
Če je potrebno se bolnike lahko zdravi s kratkodelujočimi somatostatinskimi analogi v obdobju 4 tednov pred aplikacijo zdravila Lutathera do 24 ur pred aplikacijo zdravila Lutathera.
No animal studies have been performed to determine the effects of lutetium (177Lu) oxodotreotide on the fertility of either gender.
Izvedena ni bila nobena študija na živalih za ugotavljanje učinkov lutecijevega (177Lu) oksodotreotida na plodnost katerega koli spola.
The hazard ratio for Lutathera was 0.21 (95% CI: 0.14 - 0.33), indicating 79% reduction in the risk for a patient to progress or die under Lutathera compared to octreotide LAR.
Razmerje tveganja za zdravilo Lutathera je bilo 0,21 (95-% IZ: 0,140,33), kar kaže na 79-% zmanjšanje tveganja za bolnika za napredovanje bolezni ali smrt pri zdravilu Lutathera v primerjavi z oktreotidom LAR.
Temporarily discontinue treatment with Lutathera in the following conditions:
Preglednica 4: Merila za začasno prekinitev zdravljenja z zdravilom Lutathera Zdravljenje z zdravilom Lutathera začasno prekinite v naslednjih pogojih:
During the infusion, the flow of sodium chloride 9 mg/mL (0.9%) solution for injection increases the pressure in the Lutathera vial, facilitating the flow of Lutathera into the catheter inserted in the patient's peripheral vein.
Postopek aplikacije (gravitacijska metoda) Pretok raztopine natrijevega klorida 9 mg/ml (0,9 %) raztopne za injiciranje med infuzijo poveča tlak v viali zdravila Lutathera in omogoči pretok zdravila Lutathera v kateter, vstavljen v bolnikovo periferno veno.
What you need to know before Lutathera is used Lutathera must not be used - if you are allergic to lutetium (177
Kaj morate vedeti, preden boste prejeli zdravilo Lutathera Zdravila Lutathera ne smete prejeti: - če ste alergični na lutecijev (177Lu) oksodotreotid ali katero koli sestavino tega zdravila
Any unused medicinal product or waste material should be disposed of in accordance with local requirements (see section 6.6).
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi (glejte poglavje
Major or some specific adverse reactions to Lutathera.
Pomembni ali nekateri določeni neželeni učinki zdravila Lutathera.
Talk to your nuclear medicine doctor if you are under 18 years old.
Če ste mlajši od 18 let, se pogovorite z zdravnikom nuklearne medicine, preden prejmete to zdravilo.
Renal protection and renal impairment Because lutetium (177Lu) oxodotreotide is almost exclusively eliminated through the renal system, it is mandatory to concomitantly administer an amino acid solution containing the amino acids L-lysine and L-arginine.
Lutecijev (177Lu) oksodotreotid se izloča skoraj izključno preko ledvičnega sistema, zato je treba obvezno sočasno aplicirati raztopino aminokislin, ki vsebuje aminokislini L-lizin in L-arginin.
Cryopreservation of sperm or eggs can be discussed as an option to patients before the treatment.
Z bolniki se je mogoče pred zdravljenjem pogovoriti o možnosti krioprezervacije sperme ali jajčec.
Since many patients referred for Lutathera therapy have hepatic metastasis, it may be common to observe patients with altered baseline liver function.
Veliko bolnikov, ki so napoteni na zdravljenje z zdravilom Lutathera ima metastaze v jetrih, zato so ugotovitve bolnikov s spremenjeno izhodiščno jetrno funkcijo lahko pogoste.
Close contact with other people should be restricted during 7 days following an administration of Lutathera, and for children and pregnant women it should be limited to less than 15 minutes for each day while keeping a distance of at least 1 meter.
stike z otroci in nosečnicami pa morajo omejiti na manj kot 15 minut vsak dan, pri tem pa vzdrževati razdaljo vsaj 1 metra.
Pancreatic enzymes decreased Hepatocellular injury Cholestasis
Znižana raven encimov trebušne slinavke Hepatocelularna poškodba Holestaza
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT Viala št .
b. If the observed toxicity resolves within 16 weeks after the last infusion, it is possible to continue the treatment with Lutathera by infusing a half dose (3,700 MBq)*.
b. Če opažena toksičnost izgine v 16 tednih po zadnji infuziji, je mogoče zdravljenje z zdravilom Lutathera nadaljevati z infundiranjem polovičnega odmerka
• Hematologic monitoring: white blood cells, platelets, and haemoglobin
• hematološko spremljanje: levkocite, trombocite in hemoglobin;
Hypoglycaemia Hypernatremia Hypophosphatemia Tumor lysis syndrome Hypercalcaemia Hypocalcaemia Hypoalbuminaemia Metabolic acidosis
Hipoglikemija Hipernatriemija Hipofosfatemija Sindrom tumorske lize Hiperkalcemija Hipokalcemija Hipoalbuminemija Metabolna acidoza
Deaths
Smrt
It is a ready to use radiopharmaceutical medicinal product for single use only.
Je radiofarmak, pripravljen na uporabo, in je samo za enkratno uporabo.
Swelling face Hyperhidrosis Pruritus generalized
Oteklost obraza Hiperhidroza Generalizirani pruritus
The recommended treatment regimen of Lutathera in adults consists of 4 infusions of 7,400 MBq each.
Priporočeni režim zdravljenja z zdravilom Lutathera pri odraslih sestavljajo 4 infuzije, vsaka s
Constant intra-vial pressure should be maintained during the entire infusion.
V celotnem času infundiranja je treba vzdrževati stalen tlak v viali.
The results indicate an improvement in the overall global health-related quality of life up to week 84, for patients on Lutathera treatment as compared to patients on Octreotide LAR arm.
Pri bolnikih, ki so prejemali zdravilo Lutathera, rezultati kažejo na splošno izboljšanje kakovosti življenja, povezane z zdravjem, do 84. tedna, v primerjavi z bolniki v skupini, ki je prejemala Octreotide LAR.
Additionally, due to the death and breakage of the malignant cells by the therapy, there is a possibility that you experience an excessive release of hormones from these cells increasing or triggering neuroendocrine tumour related symptoms such as diarrhoea, flushing and hot flushes, heartbeat disorder, shortness of breath, etc. Should you experience such symptoms: inform your doctor immediately, who may request that you stay at the hospital for observation and treatment if necessary.
Zaradi smrti in razpada malignih celic po zdravljenju obstaja tudi možnost, da bo pri vas prišlo do prekomernega izločanja hormonov iz teh celic, povečanja ali sprožanja simptomov, povezanih z nevroendokrinim tumorjem, kot so driska, zardevanje in vročinski oblivi, motnja bitja srca, zasoplost itd.
The PFS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 24 July 2015 is depicted in Figure 3.
Diagram Kaplan-Meier PFS za celotno skupino bolnikov (FAS) na datum za končno analizo 24. julija 2015 je prikazan v sliki 3.
How Lutathera is stored 6.
Shranjevanje zdravila Lutathera 6.
Gallbladder Wall Lower Large Intestine Wall Small Intestine Stomach Wall
Stena spodnjega debelega črevesa Tanko črevo
Nausea, vomiting, fatigue, low platelet count (thrombocytopenia), low white blood cell count (lymphopenia), low red cell count (anaemia), decreased appetite, decreased all blood cell count (pancytopenia)
občutek siljenja na bruhanje, utrujenost, zmanjšano število trombocitov (trombocitopenija), zmanjšano število belih krvnih celic (limfopenija), zmanjšano število rdečih krvnih celic (anemija), zmanjšanje apetita, zmanjšano število vseh krvnih celic (pancitopenija).
Weight decreased Blood creatine phosphokinase increased
Zvečanje vrednosti kreatin fosfokinaze v krvi
Gastrointestinal pain Stomatitis
Vstavitev gastrointestinalne cevke
• The infusion set should be connected to the bag of sodium chloride 9 mg/mL (0.9%) solution for injection and pre-filled by opening the clamp.
• Komplet za infuzijo je treba priključiti na vrečko natrijevega klorida 9 mg/ml (0,9 %) raztopine za injiciranje in predhodno napolniti z odprtjem sponke.
(not < 320 mL/h for commercial solutions)
(za komercialno dostopne raztopine ne manj kot 320 ml/h)
The vial is enclosed within a lead container for protective shielding.
Viala je zaprta v zaščitnem svinčenem vsebniku.
• Kidney failure with creatinine clearance < 50 mL/min;
• ledvična odpoved s kreatininskim očistkom < 50 ml/min;
Bone marrow function and/or blood count disorders Because of the potential for undesirable effects, blood counts must be monitored at baseline and during treatment, and until resolution of any eventual toxicity (see section 4.2).
Zaradi možnosti neželenih učinkov je treba krvno sliko nadzirati v izhodišču, med zdravljenjem in do izboljšanja katere koli morebitne toksičnosti (glejte poglavje 4.2).
If necessary, patients may be treated with short acting somatostatin analogues during the 4 weeks until 24 hours preceding Lutathera administration.
Bolnike se po potrebi lahko zdravi s kratkodelujočimi somatostatinskimi analogi v obdobju 4 tednov in do 24 ur pred aplikacijo zdravila Lutathera.
- if you have mild to moderate chronic kidney disease - if you previously received anti-cancer treatment (chemotherapy) - if you have mildly altered blood cell counts - if you have bone metastasis - if you have previously received any radionuclide therapy - if you had other type of cancer within last 5 years
- če trpite za urinarno inkontinenco (nehoteno uhajanje urina); - če imate blago do zmerno kronično bolezen ledvic; - če ste predhodno že prejemali terapijo za zdravljenje raka (kemoterapijo); - če imate blago spremenjeno število krvnih celic;
The PFS Kaplan-Meier graph for the full analysis set (FAS) at the cut-off date 30 June 2016 is depicted in Figure 4.
Diagram Kaplan Meier PFS za celotno skupino bolnikov (FAS) na končni datum 30. junija 2016 je prikazan na sliki 4.
Haematochezia Abdominal discomfort Intestinal obstruction Colitis
Hematohezija Nelagodje v trebuhu Intestinalna obstrukcija Kolitis
For instruction on preparation of the medicinal product before administration, see section 12.
Za navodila glede priprave zdravila pred aplikacijo glejte poglavje 12.
− One bag of sodium chloride 9 mg/mL (0.9%) solution for injection (500 mL)
− ena vrečka natrijevega klorida 9 mg/ml (0,9 %) raztopina za injiciranje (500 ml);
• Patients with somatostatin receptor negative or mixed visceral lesions (tumour uptake score < 2)
• bolniki z negativnim izvidom za somatostatinske receptorje ali ali mešanimi visceralnimi lezijami (z oceno privzema v tumorju < 2) po slikanju somatostatinskih receptorjev.
Ovaries**
Jajčniki**
An individual benefit-risk assessment is recommended prior to treatment with Lutathera in patients with mild and moderate renal impairment, for additional details see section 4.2 (Table 3) and section 4.4.
Pred zdravljenjem bolnikov z blago in zmerno ledvično okvaro z zdravilom Lutathera je priporočljivo oceniti koristi in tveganja pri posamezniku; za dodatne podrobnosti glejte poglavje 4.2 (preglednica 3) in 4.4.
The pharmacokinetic profile of lutetium (177Lu) oxodotreotide in patients with severe renal impairment (creatinine clearance < 30 mL/min) has not been studied, therefore treatment with Lutathera in those patients is contraindicated (see section 4.3).
Farmakokinetični profil lutecijevega (177Lu) oksodotreotida pri bolnikih s hudo ledvično okvaro (očistek kreatinina < 30 ml/min) ni bil raziskan, zato zdravljenje z zdravilom
METHOD AND ROUTE(S) OF ADMINISTRATION Single-dose vial.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Viala z enim odmerkom.
Volumetric activity at calibration time: 370 MBq/mL - {DD/MM/YYYY hh:mm UTC}
Volumetrična aktivnost v času umerjanja: 370 MBq/ml - {DD/MM/LLLL uu:mm UTC}
Renal toxicity defined as an estimated creatinine clearance < 40 mL/min, or a 40% increase compare to the baseline serum creatinine level with a decrease of over 40% compared to the baseline creatinine clearance.
povečanje v primerjavi s izhodiščno ravnjo serumske koncentracije kreatinina z več kot 40% zmanjšanjem v primerjavi z izhodiščnim kreatininskim očistkom.
Amino acid solution should be administered over 4 hour time span.
Raztopino aminokislin je treba aplicirati v 4-urnem časovnem obdobju.
Administration of long acting somatostatin analogues should be avoided within 30 days prior to the administration of Lutathera.
Apliciranju dolgodelujočih somatostatinskih analogov se je treba izogibati v obdobju 30 dni pred aplikacijo zdravila Lutathera.
METHOD OF ADMINISTRATION Single-dose vial.
POSTOPEK UPORABE Viala z enim odmerkom.
For renal protection purpose, an amino acid solution must be administered intravenously during 4 hours.
Za zaščito ledvic je treba v trajanju 4 ur intravensko infundirati raztopino aminokislin.
Breast-feeding It is unknown whether lutetium (177Lu) oxodotreotide is excreted in breast milk.
Dojenje Ni znano ali se lutecijev (177Lu) oksodotreotid izloča v materino mleko.
Herpes zoster Ophthalmic herpes zoster Influenza
Oftalmični herpes zoster
With respect to overall survival OS, at the time of interim analysis (24 July 2015), there were 17 deaths in the Lutathera arm and 31 in octreotide LAR 60 mg arm and the hazard ratio was 0.459 in favour of Lutathera, but did not reach the level of significance for interim analysis (HR 99.9915% CI: 0.140, 1.506).
Razmerje tveganja (HR - hazard ratio) je bilo 0,459 v korist zdravila Lutathera, vendar raven pomembnosti pri vmesni analizi ni bila dosežena (HR 99,9915 % IZ: 0,140, 1,506).
Health Related Quality of Life (HRQOL) was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (generic instrument) and its neuroendocrine tumour module (EORTC QLQ-GI.NET-21).
Kakovost življenja, povezano z zdravjem (Health Related Quality of Life - HRQOL) so ocenili z vprašalnikom za kakovost življenja Evropske organizacije za raziskave in zdravljenje raka (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - EORTC QLQ
• Impaired haematological function with either Hb < 4.9 mmol/L (8 g/dL), platelets < 75 G/L
• oslabljena hematološka funkcija z vrednostmi Hb < 4,9 mmol/l (8 g/dl), trombocitov < 75 g/l (75x103/mm3) ali levkocitov < 2 g/l (2.000/mm3) (razen limfopenije);
BATCH NUMBER Batch:
ŠTEVILKA SERIJE Številka serije:
OS median was 27.4 months in octreotide LAR arm and was not reached in Lutathera arm. An update conducted about one year after (30 June 2016) showed similar trend with 28 deaths in the Lutathera arm and 43 in octreotide LAR 60 mg arm, an HR of 0.536, and a median OS of 27.4 months in octreotide LAR arm and still not reached in Lutathera arm.
Posodobitev čez približno leto dni (30. junija 2016) je pokazala podoben trend s 28 smrtmi pri skupini z zdravilom Lutathera in 43 smrtmi pri skupini z oktreotidom LAR 60 mg, razmerjem tveganja 0,536, mediana OS pri oktreotidu LAR je bila 27,4 meseca, pri zdravilu Lutathera pa še vedno ni bila dosežena.
Hypersensitivity to the active substance or to any of the excipients of this medicinal product When specific adverse reactions to this medicinal product persist or reoccur, such as delayed grade 3-4 (G3-G4) hematotoxicity (see Table 5).
Če določeni neželeni učinki tega zdravila, kot je na primer hematotoksičnost razreda 3-4 (G3-G4), vztrajajo ali se ponovno pojavijo (glejte preglednico 5)
The following conclusions on treatment with Lutathera were determined from radiation dosimetry evaluations performed in clinical studies:
Na podlagi kliničnih študij z ocenami sevalne dozimetrije so bili za zdravljenje z zdravilom Lutathera določeni naslednji sklepi:
4.4 Special warnings and precautions for use
4.4 Posebna opozorila in previdnostni ukrepi Bolniki z dejavniki tveganja
Acute prerenal failure Renal impairment
Ledvična bolezen Akutna predledvična odpoved Ledvična okvara
See leaflet for further information.
Dodatne informacije so v navodilu za uporabo.
• The critical organ is the bone marrow, however, with the recommended Lutathera cumulative dose of 29,600 MBq (4 administrations of 7,400 MBq), no correlation between hematologic toxicity and the total radioactivity administered or bone marrow absorbed dose has been observed either in Erasmus phase I/II or in NETTER-1 phase III study.
• kritičen organ je kostni mozeg, vendar pri priporočenem skupnem odmerku zdravila Lutathera v višini 29,600 MBq (4 aplikacije po 7.400 MBq) v študijah Erasmus I./II.
Scheme of instructions for dose modifications
Preglednica 5: Navodila za prilagajanje odmerka
The adequate position of the catheter should be checked before and during infusion.
Pred in med infundiranjem je treba preverjati, ali je položaj katetra pravilen.
Cases of irreversible hematological pathologies, i.e., premalignant and malignant blood neoplasms (i.e., myelodysplastic syndrome and acute myeloid leukemia, respectively) have been reported following Lutathera treatment.
Po zdravljenju z zdravilom Lutathera so poročali o primerih nepovratnih hematoloških patologij, tj. predmalignih in malignih krvnih neoplazmah (tj. mielodisplastičnega sindroma oziroma akutne mieloidne levkemije).
Hepatic encephalopathy Paraesthesia Parosmia
Mravljinčenje Hepatična encefalopatija
What Lutathera contains - The active substance is lutetium (177Lu) oxodotreotide.
Kaj vsebuje zdravilo Lutathera - Učinkovina je lutecijev (177Lu) oksodotreotid.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system:
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
It is not recommended to decrease the amount of amino acid solution in case of Lutathera dose adaptation.
V primeru prilagoditve odmerka zdravila Lutathera ni priporočljivo zmanjšati količino raztopine aminokislin.
If you get any side effects, talk to your doctor.
Če opazite katerega koli izmed neželenih učinkov, se posvetujte, se posvetujte z zdravnikom.
In spite of an observed significant selective B-cell depletion, no increase in the rate of infectious complications occurs after PRRT.
Kljub opaženi pomembni selektivni izgubi B-celic se zvečanje pojavnosti komplikacij z okužbami po radionuklidni terapiji s peptidnimi receptorji (PRRT, peptide receptor radionuclide therapy) ne pojavi.
Suitable precautions in accordance with national regulations should be taken concerning the activity eliminated by the patients in order to avoid any contaminations.
Za preprečevanje kakršne koli kontaminacije vezane na aktivnost, ki jo izločijo bolniki,
Refractory cytopenia with multilineage dysplasia (Myelodysplastic syndrome)
Refraktorna citopenija z displazijo več celičnih linij (mielodisplastični sindrom)
Pancreatitis acute Rectal haemorrhage Melaena
Akutni pankreatitis Rektalna krvavitev Melena
Dishes and bathroom accessories Take special precautions during the 7 days after treatment: - Flush all wipes and/or toilet paper down the toilet immediately after use, - Always wash your hands well after using the toilet, - Take a shower every day, - Flush any tissues or any other items that contain anything from your body, such as blood, urine and faeces down the toilet.
- vse robčke in/ali ves toaletni papir takoj po uporabi odplaknite v stranišču; - po uporabi stranišča si vedno umijte roke;
To avoid treatment-related nausea and vomiting, an intravenous bolus of an antiemetic medicinal product should be injected 30 minutes before the start of amino acid solution infusion (see section
Z zdravljenjem povezanima navzei in bruhanju se izognemo z intravenskim bolusom antiemetika, ki ga je treba injicirati 30 minut pred začetkom infundiranja raztopine aminokislin (glejte poglavje 4.2).
Disposable waterproof gloves should be worn.
Nositi je treba vodotesne rokavice za enkratno uporabo.
Figure 4.
in 4.4.
Radiation dose to specific organs, which may not be the target organ of therapy, can be influenced significantly by pathophysiological changes induced by the disease process.
Patofiziološke spremembe, ki jih sproži bolezenski proces lahko bistveno vplivajo na odmerek sevanja za posamezne organe, ki niso ciljni organi pri zdravljenju.
Considering the high quantity of amino acids and the significant volume that commercially available solutions may require to meet the above specifications, the compounded solution is considered the medicinal product of choice, due to its lower total volume to be infused and lower osmolarity.
Sestavljena raztopina zaradi nižjega skupnega volumna, ki ga je treba infundirati, in nižje osmolarnosti predstavlja zdravilo prve izbire glede na veliko količino aminokislin in znaten volumen, ki bo morda potreben, da bi komercialno dostopne raztopine lahko ustrezale zgoraj navedenim specifikacijam.
Red Marrow
Rdeči kostni mozeg
2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells.
Lutecij-177 (177Lu) je radionuklid, ki oddaja β-, z največjim razponom penetracije v tkivo 2,2 mm (srednji razpon penetracije je 0,67 mm), kar zadostuje za uničenje ciljanih tumorskih celic z omejenim učinkom na sosednje normalne celice.